Related Experiment Video
Updated: Apr 12, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
How to manage thrombolysis interruptions in acute stroke?
Stefan Brodoehl1, Albrecht Günther, Otto W Witte
1Hans Berger Department of Neurology, University Hospital Jena, Jena, Germany.
Objectives:
Tissue plasminogen activator (t-PA) is the only approved thrombolytic therapy for the treatment of stroke patients. Its effectiveness is highly time dependent because of the sensitivity of brain tissue to ischemia. Because of the short half-life of t-PA, it should be administered as a bolus followed by an immediate infusion. However, in clinical practice, there are sometimes delays between the application of the bolus and the start of the infusion; in addition, interruptions of the infusion may occur. There are no recommendations regarding how to handle such situations.
Methods:
We simulate the effects on serum t-PA concentrations of different delays in administering t-PA using its known pharmacokinetic parameters in a 2-compartment model.
Results:
Our results demonstrate that even short delays of only 1 minute between bolus and infusion severely affect serum t-PA concentrations. In addition, interruptions to the infusion that are over 1 minute in duration affect serum t-PA concentrations.
Conclusions:
These results strongly suggest avoiding bolus-infusion delays by giving the bolus only when the infusion is ready. In case of a delayed start of the infusion, the possibilities are restricted to do nothing or to give a second bolus. We have estimated the dosing of the second bolus depending on the duration of the delay/interruption to allow for the achievement of appropriate serum t-PA concentrations. However, clinical safety data are needed to recommend the application of a second bolus.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism III: Nursing Management

